GI Dynamics (ASX:GID) has revealed a restructuring plan involving cutting 10% of its workforce, including CFO Robert Crane. [ + ]

CSL (ASX:CSL), Hospira and GlaxoSmithKline have partnered with META and the University of Melbourne for a project aimed at improving manufacturing efficiency at Australian sites. [ + ]

Rhinomed (ASX:RNO) has won approval from key regulators for Mute, a medical device for snoring and sleep breathing, and published top-line data from a trial of the product in snorers. [ + ]

Japanese researchers have successfully generated a kidney-like structure from just a single cell, thus making a huge leap forward in organ regeneration research. [ + ]

When scientists in the 17th century studied living organisms under an optical microscope for the first time, a new world opened up before their eyes. However, optical microscopy was limited by a physical restriction as to what size structures it was possible to resolve. Now, super-resolved fluorescence microscopy has bypassed this limitation.

Professor Andrew Holmes reflects on the role serendipitous discovery has played in his successful research career as an organic chemist and how he is now stepping into the role as President of the Australian Academy of Science. [ + ]

Imugene has announced plans to divest its drug delivery platform linguet and revealed more promising preclinical data from its HER-Vaxx immuno-oncology program. [ + ]

Circadian Technologies (ASX:CIR) has raised $17.4m through a placement and share purchase plan, and plans to use the proceeds to take OPT-302 into the clinic in wet AMD. [ + ]

GI Dynamics (ASX:GID) has received the all-clear to resume shipments of its EnBobarrier obesity and diabetes therapy in the EU following a two-month suspension. [ + ]

Genetic Technologies (ASX:GTG) has announced the resignation of CEO Alison Mew, and has secured shareholder approval to change its name to Phenogen Sciences. [ + ]

EY has released its annual medical technology report for 2014 - 'Pulse of the industry: differentiating differently'. [ + ]

Novogen (ASX:NRT) has selected the lead candidate from its family of drugs designed to complement existing chemotherapies by targeting a different part of a cancer's cytoskeleton. [ + ]

Bioprinted liver tissue containing both parenchymal and non-parenchymal cells in spatially controlled, user-defined geometries that reproduce compositional and architectural features of native tissue are making it possible to assess drug effects over timeframes much longer than those offered by 2D liver cell culture systems.

CSL (ASX:CSL) has launched a trial of CSL112 in patients at risk of recurrent cardiovascular events and presented data into the cholesterol-clearing mechanism of action behind the drug. [ + ]

Genetic Technologies (ASX:GTG) has completed the sale of its Australian genetics business to Specialist Diagnostics Services as part of its streamlining efforts. [ + ]